Real-World Data on Osimertinib-Associated Cardiac Toxicity
Journal of Clinical Medicine · 05.03.2025 · 14 (5) · 1754
DOI: 10.3390/jcm14051754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.03.2025. Verfasst von Abed Agbarya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Bnai Zion Medical Centre, Haifa 31048, Israel. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lung cancer is the leading cause of cancer-related deaths globally, with epidermal growth factor receptor (EGFR) mutations present in approximately 17–39% of non-small cell lung cancer (NSCLC) cases. Osimertinib, a third-generation oral EGFR tyrosine kinase inhibitor (EGFR-TKI), has become a cornerstone in the treatment of EGFR-mutated NSCLC. However, the full scope of its potentially life-threatening adverse effects, particularly cardiomyopathy, remains underexplored.
Methods
This retrospective study was conducted using data from a multi-center registry of NSCLC patients with EGFR mutations treated with first-line osimertinib therapy between December 2018 and April 2024. Osimertinib-related cardiotoxicity was defined as a composite of reduced ejection fraction (EF) and cardiac death.
Results
The study cohort consisted of 17 patients, and most of the patients had a history of smoking. Cardiac toxicity onset varied from 1 to 28 months following osimertinib initiation, with 70.59% of the patients experiencing symptoms within the first 6 months of treatment. Fourteen patients showed some degree of symptom improvement and EF recovery, although most did not return to baseline EF levels. Comorbidities, including heart failure, hypertension, and dyslipidemia, were prevalent across the cohort.
Conclusions
While osimertinib remains an effective treatment for EGFR-mutated NSCLC, its associated cardiac toxicity, particularly in patients with pre-existing conditions, presents a significant challenge. Close monitoring, early intervention, and individualized management strategies are critical in mitigating these risks. Patients with mild cardiac toxicity may be suitable for rechallenge, while those with more severe or persistent toxicity should generally be excluded from further osimertinib treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oncology Department, Bnai Zion Medical Centre, Haifa 31048, Israel.
- Thoracic Cancer Service, Davidoff Cancer Centre, Beilinson Campus, Petah Tikva 49100, Israel.
- Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan 52600, Israel.
- School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
- Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem 91200, Israel.
- Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska st. 976/3, 77900 Olomouc, Czech Republic.
ORCID-Profile: Abed Agbarya, Hadas Gantz Sorotsky, Johnathan Arnon, Walid Shalata
Zitieren
APA
Agbarya, A., Raphael, A., Gantz Sorotsky, H., Rottenberg, Y., Šebek, V., Radonjic, D., Yakobson, A., Arnon, J., & Shalata, W. (2025). Real-World Data on Osimertinib-Associated Cardiac Toxicity. Journal of Clinical Medicine, 14(5), 1754. https://doi.org/10.3390/jcm14051754
Vancouver
Agbarya A, Raphael A, Gantz Sorotsky H, Rottenberg Y, Šebek V, Radonjic D, et al. Real-World Data on Osimertinib-Associated Cardiac Toxicity. Journal of Clinical Medicine. 2025;14(5):1754. doi:10.3390/jcm14051754
BibTeX
@article{Agbarya2025,
author = {Agbarya, Abed and Raphael, Ari and Gantz Sorotsky, Hadas and Rottenberg, Yakir and Šebek, Viktor and Radonjic, Dejan and Yakobson, Alexander and Arnon, Johnathan and Shalata, Walid},
title = {Real-World Data on Osimertinib-Associated Cardiac Toxicity},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {5},
pages = {1754},
doi = {10.3390/jcm14051754}
}
EUVIMED